Application of kaempferol 3-glucorhamnoside in preparation of medicine for treating systemic severe sepsis

A technology of bakinosu and sepsis, which is applied in the field of biomedicine to achieve the effect of reducing lung damage, improving and treating severe sepsis

Inactive Publication Date: 2020-03-06
CHINA AGRI UNIV +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to enrich the medical use of thymelin I and to address the problem of insufficient treatment of severe sepsis in the prior art, to propose a use of thymosin I in the preparation of drugs for the treatment of severe sepsis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kaempferol 3-glucorhamnoside in preparation of medicine for treating systemic severe sepsis
  • Application of kaempferol 3-glucorhamnoside in preparation of medicine for treating systemic severe sepsis
  • Application of kaempferol 3-glucorhamnoside in preparation of medicine for treating systemic severe sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Effects of thymosin I on cell viability

[0038] experimental method

[0039] Experimental grouping: blank control group, LPS group, thymosin I group

[0040] RAW 264.7 cells were seeded into 96-well plates (2×10 4 Cells / well) were cultured for 24 hours and added with a concentration of 4 μg / ml thymeclidin I, the treatment time was 1 hour, and then exposed to LPS for 18 hours. Subsequently, the 96-well plate was washed twice with PBS, MTT (5 mg / ml) was added to the cells, and incubated for another 4 hours. Add DMSO to dissolve, and measure the absorbance at 570nm; the blank control group is not subjected to any treatment, and the LPS group is only treated with LPS, without treatment with thymosin I.

[0041] Experimental results

[0042] Table 1 Effect of thymosin I on cell viability

[0043]

[0044] (All data are expressed as mean ± SEM (n = 5) ## P* P** P<0.01, compared with LPS group. )

[0045] The cell viability of RAW264.7 cells treated with thymosin I...

Embodiment 2

[0047] Anti-inflammatory effect of thymosin I on cells

[0048] experimental method

[0049] Experimental grouping and drug treatment were the same as in Example 1, with 5 replicate wells set up for each group. After drug treatment, the cells were placed at 37°C, 5% CO 2 Continuously cultured in the incubator for 72 hours, after that, the cells were blown evenly in a 96-well plate, the cell suspension was collected, centrifuged (3000r / min, 20min), and the cell supernatant was collected. The operation steps were carried out according to the instructions of the ELISA detection kit. Content of TNF-α, IL-10, IL-6.

[0050] Experimental results

[0051] Table 2 The effect of thymosin I on the secretion of inflammatory cytokines in LPS-challenged RAW264.7 cells

[0052]

[0053]

[0054] (All data are expressed as mean ± SEM (n = 5) ## P* P** P<0.01, compared with LPS group. )

[0055] The contents of TNF-α, IL-6 and IL-10 in RAW264.7 cells treated with thymosin I (4 μg / ml...

Embodiment 3

[0057] Effects of thymosin I on TNF-α, IL-10 and IL-6 in mouse serum, liver, spleen and lung

[0058] (1) The effect of thymosin I on the contents of TNF-α, IL-10 and IL-6 in the supernatant of liver homogenate.

[0059] experimental method

[0060] Experimental grouping: blank control group, thymosin I group, LPS group

[0061] 18 mice were randomly divided into blank control group, thymosin I group (200 μg / ml), LPS group (10 mg / kg), 6 mice in each group. 200 μg / ml of thymelin I was injected into the mice of thymelin I, and after 1 hour of treatment, the thymelin I group and the LPS group were challenged; the blank control group did not receive any treatment. Collect the mouse serum, liver, spleen and lungs of each group and make a tissue homogenate suspension, dilute the tissue homogenate suspension 10 times, centrifuge at 3600r / min for 10 minutes, and collect the homogenate supernatant; after that, according to ELISA The test kit instructions are used to detect the level...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of kaempferol 3-glucorhamnoside in preparation of a medicine for treating systemic severe sepsis, and belongs to the technical field of biological medicines. The inventor of the invention finds that the kaempferol 3-glucorhamnoside can improve and treat the severe sepsis by reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in serum, reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the liver, reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the lung, and reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the spleen. Secondly, the kaempferol 3-glucorhamnoside can improve and treat the severe sepsis by reducing lung injury caused by the severe sepsis and inhibiting increase of phosphorylation degree of ERK1/2, JNK and p38 and increase of phosphorylation degree of I kappa B and NF-kappa B caused by severe sepsis. Therefore, the kaempferol3-glucorhamnoside can be used for preparing a potential medicine for treating diseases related to the systemic severe sepsis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the use of thymosin I in the preparation of medicines for treating systemic severe sepsis. Background technique [0002] Sepsis is a life-threatening medical illness characterized by a dysregulated immune response induced by infection leading to life-threatening multiple organ dysfunction. Sepsis is an excessive inflammatory response caused by stimulation of the body due to the rapid reproduction of various pathogenic bacteria and the production of a large amount of toxins after entering the body's blood system. [0003] Severe sepsis is a type of sepsis. Severe sepsis is dangerous and has a high mortality rate. Most patients are accompanied by organ dysfunction and acute lung injury. The main difficulty in the treatment of severe sepsis is Difficult to diagnose and difficult to treat. So far, there is no effective treatment for severe sepsis. Therefore, the dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P31/04
CPCA61K31/7048A61P31/04
Inventor 郝智慧候冉冉李秋孙卓建黄亭亭
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap